双相障碍药物维持治疗与精神科住院风险
该研究利用全国登记数据识别35 022例双相障碍患者,分析2006至2009年间锂盐、丙戊酸盐、卡马西平、拉莫三嗪、喹硫平和奥氮平治疗与精神科住院的关系。结果显示锂盐、丙戊酸盐、拉莫三嗪、奥氮平和喹硫平与住院率降低相关,锂盐效果优于喹硫平和奥氮平,且药物效应取决于心境发作极性。
要点
- 锂盐、丙戊酸盐、拉莫三嗪、奥氮平和喹硫平均与精神科住院率降低相关。
- 在常规临床实践中锂盐预防住院的效果优于喹硫平和奥氮平。
- 不同药物的效果取决于心境发作的极性。
核心结论
- 锂盐、丙戊酸盐、拉莫三嗪、奥氮平和喹硫平与双相障碍患者精神科住院率降低相关,锂盐效果优于喹硫平和奥氮平。
研究设计与样本
- 利用全国登记数据识别35 022例双相障碍患者,收集2006至2009年锂盐、丙戊酸盐、卡马西平、拉莫三嗪、喹硫平和奥氮平治疗信息。
- 采用分层Cox回归比较同一个体用药期与未用药期的精神科住院情况。
主要发现
- 锂盐、丙戊酸盐、拉莫三嗪、奥氮平和喹硫平治疗与住院率降低相关。
- 锂盐比喹硫平和奥氮平更有效。
- 特定药物的效果取决于心境发作的极性。
临床怎么用
- 在常规临床实践中,锂盐可作为双相障碍维持治疗预防住院的优先选择之一。
- 选择维持治疗药物时需考虑心境发作极性对药物效果的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BackgroundClinical trials have examined the efficacy of drugs to prevent relapse in patients with bipolar disorder, however, their design often limits generalisation to routine clinical practice.AimsTo estimate the effectiveness of drugs used for maintenance treatment in bipolar disorder.MethodWe used national registers to identify 35 022 individuals diagnosed with bipolar disorder and information on lithium, valproate, carbamazepine, lamotrigine, quetiapine and olanzapine treatment from 2006 to 2009. The main outcome was psychiatric hospital admissions. We used stratified cox regression to compare periods on and off medication within the same individual.ResultsMedication with lithium, valproate, lamotrigine, olanzapine and quetiapine was associated with reduced rates of admission to hospital. Lithium was more effective than quetiapine and olanzapine. The effects of specific drugs depended on the polarity of the mood episode.ConclusionsOur findings complement results from randomised controlled trails, but suggest that lithium is more effective than both quetiapine and olanzapine in routine clinical practice.
引用
- Joas E, Karanti A, Song J, et al. Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder. Br J Psychiatry. 2017. PMID: 28104736. doi:10.1192/bjp.bp.116.187989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。